NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, today announced further equity investment of £490k from Parkinson’s UK, to support the development of disease modifying drugs for the treatment of Parkinson’s. Following positive progress, this is the third investment Parkinson’s UK has made into NRG Therapeutics, bringing the total amount […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2021-08-23 08:00:052026-07-31 12:38:37Parkinson’s UK invests a further £490k in NRG Therapeutics to Progress Parkinson’s Drug Discovery Programme
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announced that it has been awarded a $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s. NRG Therapeutics is applying […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2021-07-29 08:00:482026-07-31 12:39:21NRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation to Progress Parkinson’s Programme
Parkinson’s UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme. This funding boost, on top of an initial £1 million investment, will support the development of a breakthrough drug with the potential to slow or halt the progression of Parkinson’s – something no known treatment can currently do. Initiated […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2020-08-07 08:00:432026-07-31 12:40:50Parkinson’s UK continues drug discovery with NRG Therapeutics Ltd
Richard brings over 25 years of experience in scientific translation working with companies, charities and universities to accelerate drug development. During his time at The Wellcome Trust Richard established a £200 million Seeding Drug Discovery fund which facilitated small molecule development and early stage clinical studies and saw over 30 of its programmes progress to […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2019-11-05 08:00:002026-07-31 12:42:56Dr Richard Seabrook joins Board of NRG Therapeutics
Parkinson’s UK invests a further £490k in NRG Therapeutics to Progress Parkinson’s Drug Discovery Programme
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, today announced further equity investment of £490k from Parkinson’s UK, to support the development of disease modifying drugs for the treatment of Parkinson’s. Following positive progress, this is the third investment Parkinson’s UK has made into NRG Therapeutics, bringing the total amount […]
NRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation to Progress Parkinson’s Programme
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announced that it has been awarded a $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s. NRG Therapeutics is applying […]
Parkinson’s UK continues drug discovery with NRG Therapeutics Ltd
Parkinson’s UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme. This funding boost, on top of an initial £1 million investment, will support the development of a breakthrough drug with the potential to slow or halt the progression of Parkinson’s – something no known treatment can currently do. Initiated […]
Dr Richard Seabrook joins Board of NRG Therapeutics
Richard brings over 25 years of experience in scientific translation working with companies, charities and universities to accelerate drug development. During his time at The Wellcome Trust Richard established a £200 million Seeding Drug Discovery fund which facilitated small molecule development and early stage clinical studies and saw over 30 of its programmes progress to […]